Brought to you by 
Reata brings in $17mm so far via its Series G round; adds $61mm
12 Jul 2010
Executive Summary
Reata Pharmaceuticals (developing therapeutics for inflammation) has brought in $17mm so far through its Series G venture round from 30 investors. According to the company's Form D filing, it could bring in a total of $79.3mm. The second tranche of the money is linked to the success of Reata's Phase IIb trial of bardoxolone for diabetics with advanced chronic kidney disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Reata brings in $17mm so far via its Series G round; adds $61mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice